What Research Peptides Actually Cost — And Why Price Per Milligram Tells You Almost Nothing

Anyone comparing research peptide suppliers arrives at the same question within about ten minutes: why does a 10 mg vial cost £28 from one source and £115 from another, when both certificates say 99% purity? It is a reasonable question, and the usual answers — brand premium, marketing spend, someone is overcharging — are mostly wrong. Peptide manufacture has an unusually well-documented cost structure, and the published data explain nearly all of the spread in research peptide price.

Peptides Are Materially Expensive to Make, and the Data Say So

In 2024, fourteen member companies of the ACS Green Chemistry Institute Pharmaceutical Roundtable — including Novo Nordisk, Pfizer, GSK, PolyPeptide and Bachem — published the most comprehensive analysis yet of peptide manufacturing efficiency, covering forty separate commercial and late-stage processes. Their metric is Process Mass Intensity (PMI): kilograms of total material input per kilogram of finished active substance.

• Small-molecule drugs: PMI 168–308
• Synthetic oligonucleotides: ~4,299 average
• Synthetic peptides (SPPS, commercial/Phase 3): 1,684–34,585, average 13,063
• Synthetic peptides (early development): ~33,141 average
• Biopharmaceuticals: ~8,300

A commercial-scale synthetic peptide consumes, on average, roughly forty to seventy times more material per kilogram of product than a small-molecule drug. That is not inefficiency — it is the arithmetic of solid-phase peptide synthesis, where every amino acid added requires coupling, washing, deprotection and washing again. The wash solvent alone, dimethylformamide, accounts for 39% of total solvent mass across the processes surveyed.

Length Is the Single Largest Cost Multiplier

The same dataset breaks PMI down per amino acid residue: an average of 874.5 for commercial and Phase 3 SPPS processes, rising to 1,464 for early-development material. For comparison, an oligonucleotide costs roughly 199 PMI units per building block — adding an amino acid is about 4.4 times more material-intensive than adding a nucleotide.

Industrial process guidance targets a cycle time of no more than three hours per residue including all handling operations. Apply that arithmetic and a 15-residue peptide represents roughly 45 hours of reactor occupancy before cleavage; a 31-residue backbone is closer to 90 hours. Reactor time scales linearly with sequence length while yield scales geometrically — each coupling step is high-yielding but never quite 100%, and the losses compound. The practical ceiling for efficient SPPS sits at around 100 amino acids.

This is why a short peptide and a long one are not the same commercial proposition even at identical milligram weights, and why a supplier charging the same per milligram across a catalogue of very different sequences is telling you something about their pricing model rather than their cost base.

Difficult Sequences Cost More Than Difficult-Sounding Ones

Some sequences are simply harder. The published industrial view is blunt: when synthesising longer peptides, inefficient coupling reactions, low yield and excessive impurity formation are often traceable to the growing protected chain forming secondary structures on the resin — the chain folds on itself and the next residue cannot reach its coupling site.

The evidence for how badly this bites is unusually direct. In a study of 98 synthetic peptides ordered from two international suppliers at a specified minimum 95% purity, all nine cyclic peptides in the batch failed to exceed 90% purity, and eight of the nine came in below 80%. When challenged, the suppliers conceded they could not make those sequences to the requested specification. Every one had arrived with a certificate claiming at least 95%.

Cyclic, disulfide-bridged and aggregation-prone sequences are the worst value per advertised milligram in any catalogue. Solvent choice alone moves the outcome measurably: in one published octapeptide model, crude purity ranged from 86% in DMF down to 51% in DMPU depending purely on the reaction solvent.

Purification Is Where the Price Is Actually Set

Synthesis and purification together account for 30–70% of total PMI across development stages — and purification’s share rises in commercial-stage processes specifically because the purity expectation is higher. The published data confirm directly what the industry knows: a tighter purity specification costs more per kilogram, and there is no way around it.

What a well-developed purification actually looks like, from a GMP manufacturer’s published worked example: a ~0.5 kg batch entering at roughly 74% crude purity, passing through two chromatographic steps — ion exchange, then reversed phase — and emerging above 99.5% purity with an overall molar yield above 80%.

The trade-off is measurable within a single run. In one documented preparative separation of crude bradykinin at 84.6% starting purity, volume-overloaded loading achieved 100% purity at 77% recovery, while a concentration-overload strategy achieved the same purity at 97% recovery. Same material, same target, twenty points of yield difference depending on how the column was run. Every purification pass removed shows up as margin — and it does not show up on a chromatogram that the seller chose the method for.

The Milligrams You Are Comparing May Not Be Peptide

A lyophilised peptide vial contains peptide — and also counterion, water, and residual salts from purification. Reversed-phase purification uses trifluoroacetic acid as an ion-pairing agent, so peptides are typically isolated as TFA salts. TFA contributes roughly 114 Da per basic site: the free N-terminus, plus every arginine, lysine and histidine in the sequence.

The worked arithmetic published by peptide manufacturers: a peptide of molecular weight 1000 Da with a free N-terminus and one arginine has a theoretical net peptide content of 1000 ÷ (1000 + 2 × 114) = 81%, before any water is counted. Industry-typical net peptide content for lyophilised material is quoted at 60–90% by one GMP supplier and 50–90% by another, depending on sequence, purity and purification method.

So a vial labelled "10 mg, 99% purity" with 70% net peptide content holds around 7 mg of peptide. The certificate is not lying. Purity and content are simply different quantities: purity is the main peak as a percentage of total peak area on a chromatogram; net peptide content is how many milligrams of peptide are in the vial.

The pathological version of this gap is documented. In a 2024 JAMA Network Open analysis of semaglutide vials test-purchased without prescription online, LC-MS chromatograms showed a single clean peak with no peptide-like impurities — by the vendors’ own metric, immaculate material. Measured polypeptide concentration in those same vials was 14.37%, 8.97% and 7.70% against a stated claim of at least 99% purity.

What a Low Price Actually Removes

Set aside outright fraud and the mechanism is mundane. Cheap peptides are cheap because specific, identifiable costs have been removed:

• Fewer or less selective purification passes. In the 98-peptide study, only 43 met the 95% specification their certificates claimed — traced to the supplier’s own chromatographic method lacking selectivity. One peptide reported at ≥95.0% by the supplier measured 80.6% under a selective method.
• No pyrogen control. In the largest available dataset of consumer-submitted research peptide tests — 6,285 samples across 14 compounds — endotoxin data existed for fewer than 4% of them. Chromatographic purity predicted endotoxin essentially not at all (R² below 0.01, p = 0.75).
• No batch discipline upstream. The FDA has inspected 48 GLP-1 API manufacturing sites and found 21% non-compliant with current good manufacturing practice, alongside a documented pattern of firms registering, offering product, refusing inspection and then deregistering.
• Cheaper molecules wearing the right label. Analyses of seized material have identified glycine-extended GHRP analogues and a 192-amino-acid growth hormone variant carrying an extra N-terminal alanine — near-analogues that are cheaper to make and pass a loose mass check.

One widely held assumption deserves correcting. The largest dataset does not show systematic underdosing: median measured abundance was 101.80% of label, and the vials in the 2024 test-purchase study were actually overfilled by 29–39% in absolute semaglutide mass. The documented failure in this market is variance and contamination, not short measure. Cheap material is not reliably less; it is reliably less predictable.

How to Read a Price Properly

Price per milligram is a denominator problem. Before it means anything, the numerator has to be defined:

• Net peptide content, without which the milligram figure is gross fill weight rather than peptide mass.
• Water content, since lyophilised cake is hygroscopic and water is both dead mass and a degradation accelerant.
• Counterion identity and quantity — TFA at ~114 Da per basic residue is the largest non-peptide mass sink in the vial.
• A disclosed analytical method, run on the specific lot by a laboratory independent of the seller.

A higher price does not guarantee any of these. But a price that is dramatically lower has to have come from somewhere, and the published cost structure is narrow enough that the possibilities are countable. The wider verification sequence — including identity confirmation and pyrogen testing — is set out in How Research Peptide Vials Fail Quality Control.

Related Research